{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:18:52Z","timestamp":1762507132161,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00280-017-3391-9","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T17:05:28Z","timestamp":1500570328000},"page":"583-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy"],"prefix":"10.1007","volume":"80","author":[{"given":"Mehmet Asim","family":"Bilen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth R.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amado J.","family":"Zurita-Saavedra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul G.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Stover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue-Hwa","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ming","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"3391_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422","journal-title":"N Engl J Med"},{"key":"3391_CR2","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","volume":"24","author":"EJ Small","year":"2006","unstructured":"Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089\u20133094","journal-title":"J Clin Oncol"},{"key":"3391_CR3","unstructured":"http:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/ucm210012.htm"},{"key":"3391_CR4","doi-asserted-by":"crossref","unstructured":"Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine\u2013Dendreon. Drugs R D 2006;7:197-201","DOI":"10.2165\/00126839-200607030-00006"},{"key":"3391_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrc2621","volume":"9","author":"B Psaila","year":"2009","unstructured":"Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9:285\u2013293","journal-title":"Nat Rev Cancer"},{"key":"3391_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239\u2013252","journal-title":"Nat Rev Cancer"},{"key":"3391_CR7","unstructured":"http:\/\/ssdi.genealogy.rootsweb.com\/"},{"key":"3391_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/jnci\/djr514","volume":"104","author":"ML Huber","year":"2012","unstructured":"Huber ML, Haynes L, Parker C, Iversen P (2012) Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 104:273\u2013279","journal-title":"J Natl Cancer Inst"},{"key":"3391_CR9","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","volume":"81","author":"PF Schellhammer","year":"2013","unstructured":"Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW (2013) Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 81:1297\u20131302","journal-title":"Urology"},{"key":"3391_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"3391_CR11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V81.3.610.610","volume":"81","author":"N Katayama","year":"1993","unstructured":"Katayama N, Clark SC, Ogawa M (1993) Growth factor requirement for survival in cell-cycle dormancy of primitive murine lymphohematopoietic progenitors. Blood 81:610\u2013616","journal-title":"Blood"},{"key":"3391_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/ncb2861","volume":"15","author":"P Bragado","year":"2013","unstructured":"Bragado P, Estrada Y, Parikh F et al (2013) TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha\/beta signalling. Nat Cell Biol 15:1351\u20131361","journal-title":"Nat Cell Biol"},{"key":"3391_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccr.2011.11.002","volume":"20","author":"X Lu","year":"2011","unstructured":"Lu X, Mu E, Wei Y et al (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20:701\u2013714","journal-title":"Cancer Cell"},{"key":"3391_CR14","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1182\/blood-2012-12-475483","volume":"121","author":"B Boyerinas","year":"2013","unstructured":"Boyerinas B, Zafrir M, Yesilkanal AE, Price TT, Hyjek EM, Sipkins DA (2013) Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 121:4821\u20134831","journal-title":"Blood"},{"key":"3391_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1046\/j.1537-2995.2001.41020206.x","volume":"41","author":"C Dosquet","year":"2001","unstructured":"Dosquet C, Chen Y, Makke J et al (2001) Cytokines and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization. Transfusion 41:206\u2013212","journal-title":"Transfusion"},{"key":"3391_CR16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960\u20131964","journal-title":"Science"},{"key":"3391_CR17","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","volume":"353","author":"F Pages","year":"2005","unstructured":"Pages F, Berger A, Camus M et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654\u20132666","journal-title":"N Engl J Med"},{"key":"3391_CR18","doi-asserted-by":"publisher","first-page":"e24116","DOI":"10.4161\/onci.24116","volume":"2","author":"N Halama","year":"2013","unstructured":"Halama N, Spille A, Lerchl T et al (2013) Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Oncoimmunology 2:e24116","journal-title":"Oncoimmunology"},{"key":"3391_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fonc.2015.00128","volume":"5","author":"A Strasner","year":"2015","unstructured":"Strasner A, Karin M (2015) Immune infiltration and prostate cancer. Front Oncol 5:128","journal-title":"Front Oncol"},{"key":"3391_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/bonekey.2014.95","volume":"3","author":"AH Capietto","year":"2014","unstructured":"Capietto AH, Faccio R (2014) Immune regulation of bone metastasis. Bonekey Rep 3:600","journal-title":"Bonekey Rep"},{"key":"3391_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.4161\/cbt.11.11.15543","volume":"11","author":"MR Shurin","year":"2011","unstructured":"Shurin MR, Naiditch H, Zhong H, Shurin GV (2011) Regulatory dendritic cells: new targets for cancer immunotherapy. Cancer Biol Ther 11:988\u2013992","journal-title":"Cancer Biol Ther"},{"key":"3391_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162\u2013174","journal-title":"Nat Rev Immunol"},{"key":"3391_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature09707","volume":"470","author":"W Tan","year":"2011","unstructured":"Tan W, Zhang W, Strasner A et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470:548\u2013553","journal-title":"Nature"},{"key":"3391_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature04524","volume":"440","author":"DH Jones","year":"2006","unstructured":"Jones DH, Nakashima T, Sanchez OH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692\u2013696","journal-title":"Nature"},{"key":"3391_CR25","doi-asserted-by":"publisher","first-page":"10044","DOI":"10.1158\/0008-5472.CAN-10-1254","volume":"70","author":"RH Goldstein","year":"2010","unstructured":"Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M (2010) Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Res 70:10044\u201310050","journal-title":"Cancer Res"},{"key":"3391_CR26","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang QW, Liu L, Gong CY et al (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7:e50946","journal-title":"PLoS ONE"},{"issue":"11","key":"3391_CR27","doi-asserted-by":"publisher","first-page":"dju268","DOI":"10.1093\/jnci\/dju268","volume":"106","author":"L Fong","year":"2014","unstructured":"Fong L, Carroll P, Weinberg V et al (2014) Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 106(11):dju268","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3391-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3391-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:29:50Z","timestamp":1589628590000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3391-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3391-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2017,7,20]]},"assertion":[{"value":"25 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}